72 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Tiihonen J, et al. Real-­world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017; 74:686–693.
2. Kirson NY, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74:568–575.
3. Marcus SC, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-­acting injectable anti­ psychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21:754–768.
4. Nielsen RE, et al. Second-­generation LAI are associated to favorable outcome in a cohort of incident patients diagnosed with schizophrenia. Schizophr Res 2018; 202:234–240.
5. Kishimoto T, et al. Effectiveness of long-­acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-­analysis of prospective and retrospective cohort studies. Schizophr Bull 2018; 44:603–619.
6. Ceraso A, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020; 8:CD008016.
7. Ostuzzi G, et al. Oral and long-­acting antipsychotics for relapse prevention in schizophrenia-­spectrum disorders: a network meta-­analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022; 21:295–307.
8. Wang D, et al. Long-­acting injectable second-­generation antipsychotics vs placebo and their oral formulations in acute schizophrenia: a systematic review and meta-­analysis of randomized-­controlled-­trials. Schizophr Bull 2024; 50:132–144.
9. Efthimiou O, et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-­analyses combining evidence from randomised controlled trials and real-­world data. Lancet Psychiatry 2024; 11:102–111.
10. Barnes T, et al. Evidence-­based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharm 2020; 34:3–78.
11. Kane JM, et  al. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry 2019; 80:IN18031AH18031C.
12. Kishimoto T, et al. Long-­acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-­analysis of randomised, cohort, and pre-­post studies. Lancet Psychiatry 2021; 8:387–404.
13. Wang D, et al. Efficacy, acceptability and side-­effects of oral versus long-­acting -­ injectables antipsychotics: systematic review and network meta-­analysis. Eur Neuropsychopharmacol 2024; 83:11–18.
14. Rubio JM, et al. Psychosis relapse during treatment with long-­acting injectable antipsychotics in individuals with schizophrenia-­spectrum disorders: an individual participant data meta-­analysis. Lancet Psychiatry 2020; 7:749–761.
15. Laing E, et al. Relapse and frequency of injection of monthly paliperidone palmitate—a retrospective case-­control study. Eur Psychiatry 2021; 64:e11.
16. Pappa S, et al. Partial compliance with long-­acting paliperidone palmitate and impact on hospitalization: a 6-­year mirror-­image study. Ther Adv Psychopharmacol 2020; 10:2045125320924789.
17. Turkoz I, et al. Comparative effectiveness study of paliperidone palmitate 6-­month with a real-­world external comparator arm of paliperidone palmitate 1-­month or 3-­month in patients with schizophrenia. Ther Adv Psychopharmacol 2023; 13:20451253231200258.
18. Clark I, et al. Clinical outcomes with paliperidone palmitate 3-­monthly injection as monotherapy: observational 3-­year follow-­up of patients with schizophrenia. Eur Psychiatry 2024; 67:e15.
19. Clark I, et al. Long term impact of 3-­monthly paliperidone palmitate on hospitalisation in patients with schizophrenia: six-­year mirror image study. Acta Psychiatr Scand 2024; 150:48–­50.
20. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178] 2014 (last checked February 2024); https://www.nice.org.uk/guidance/cg178.
21. Boyer L, et al. Real-­world effectiveness of long-­acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-­spectrum disorders. Mol Psychiatry 2023; 28:3709–3716.
22. McCutcheon R, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018; 137:39–46.
23. Barnes T, et al. Antipsychotic long acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009; 52:S37–S42.
24. Brissos S, et al. The role of long-­acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4:198–219.
25. Lambert P. Prescribing patterns and determinants of use of antipsychotic long-­acting injections: an international perspective. In: Antipsychotic Long-­Acting Injections, 2nd edn. Oxford: Oxford University Press; 2016:279–310.
26. Patel MX, et al. Attitudes of European physicians towards the use of long-­acting injectable antipsychotics. BMC Psychiatry 2020; 20:123.
27. Kane JM, et al. Patients with early-­phase schizophrenia will accept treatment with sustained-­release medication (long-­acting injectable anti­ psychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 2019; 80:18m12546.
28. Iyer S, et al. A qualitative study of experiences with and perceptions regarding long-­acting injectable antipsychotics: part II-­physician perspectives. Can J Psychiatry 2013; 58:23s–29s.
29. Kane JM, et al. Treatment journey from diagnosis to the successful implementation of a long-­acting injectable antipsychotic agent in young adults with schizophrenia. J Clin Psychiatry 2023; 84:22m14544.
30. Correll CU, et al. Pharmacokinetic characteristics of long-­acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs 2021; 35:39–59.
31. Kane JM, et  al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554–560.
32. Taylor D. Establishing a dose–response relationship for haloperidol decanoate. Psychiatr Bull 2005; 29:104–107.

80 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 33. McEvoy JP, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 2014; 311:1978–­1987. 34. Bailey L, et al. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia: a systematic review of the literature. Psychopharmacology (Berl) 2019; 236:3081–3092. 35. Uchida H, et al. Monthly administration of long-­acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 2008; 69:1281–1286. 36. Ikai S, et al. Plasma levels and estimated dopamine D(2) receptor occupancy of long-­acting injectable risperidone during maintenance treatment of schizophrenia: a 3-­year follow-­up study. Psychopharmacology (Berl) 2016; 233:4003–4010. 37. Hill AL, et al. Dose-­associated changes in safety and efficacy parameters observed in a 24-­week maintenance trial of olanzapine long-­acting injection in patients with schizophrenia. BMC Psychiatry 2011; 11:28. 38. Jones JC, et al. Investigation of depot neuroleptic injection site reactions. Psychiatr Bull 1998; 22:605–607. 39. Zolezzi M, et al. Long-­acting injectable antipsychotics: a systematic review of their non-­systemic adverse effect profile. Neuropsychiatr Dis Treat 2021; 17:1917–1926. 40. Coppola D, et al. A one-­year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 2012; 12:26. 41. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-­monthly in adult schizophrenia: an open-­label, parallel-­ arm, multiple-­dose study. Schizophr Res 2013; 150:281–288. 42. Paton C, et  al. Side-­effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. Ther Adv Psychopharmacol 2021; 11:2045125321991278. 43. Doshi JA, et al. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-­acting injectable antipsychotics post-­ hospital discharge. J Clin Psychopharmacol 2015; 35:442–446. 44. Correll CU, et al. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-­acting injectable antipsychotics. CNS Spectr 2019; 24:354–370. 45. Ostuzzi G, et al. Maintenance treatment with long-­acting injectable antipsychotics for people with nonaffective psychoses: a network meta-­ analysis. Am J Psychiatry 2021; 178:424–436. 46. Jann MW, et al. Long-­acting injectable second-­generation antipsychotics: an update and comparison between agents. CNS Drugs 2018; 32:241–257. 47. Correll CU, et  al. The use of long-­acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 2016; 77:1–24. 48. Nussbaum AM, et al. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012; (6):CD008296. 49. Sampson S, et al. Risperidone (depot) for schizophrenia. Cochrane Database Syst Rev 2016; 4:CD004161. 50. Citrome L. Olanzapine pamoate: a stick in time? Int J Clin Pract 2009; 63:140–150. 51. Luedecke D, et al. Post-­injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs 2015; 29:41–46. 52. Harrison TS, et al. Long-­acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18:113–132. 53. Knox ED, et al. Clinical review of a long-­acting, injectable formulation of risperidone. Clin Ther 2004; 26:1994–2002.